Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences
Based in Cambridge, MA, Merida develops biologic drugs that are engineered to selectively degrade pathogenic autoantibodies linked to a number of immune-mediated conditions. Merida has said its precision degradation approach aims to address the biological cause of these diseases, rather than broadly suppressing the immune system as done by many current treatments.